Confidence in Concept 2012 - Dundee
Lead Research Organisation:
University of Dundee
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
People |
ORCID iD |
| Michael Ferguson (Principal Investigator) |
Publications
Martins Da Silva SJ
(2017)
Drug discovery for male subfertility using high-throughput screening: a new approach to an unsolved problem.
in Human reproduction (Oxford, England)
McBrinn RC
(2019)
Novel pharmacological actions of trequinsin hydrochloride improve human sperm cell motility and function.
in British journal of pharmacology
Prati F
(2018)
Screening of a Novel Fragment Library with Functional Complexity against Mycobacterium tuberculosis InhA.
in ChemMedChem
Varshney D
(2016)
Molecular basis of RNA guanine-7 methyltransferase (RNMT) activation by RAM.
in Nucleic acids research
| Description | A Centre of Excellence for Lead Optimisation for Diseases of the Developing World |
| Amount | £100,000 (GBP) |
| Funding ID | OPP1066891 |
| Organisation | Bill and Melinda Gates Foundation |
| Sector | Charity/Non Profit |
| Country | United States |
| Start | 06/2013 |
| End | 06/2018 |
| Description | Confidence in Concept 2013 |
| Amount | £800,000 (GBP) |
| Funding ID | MC_PC_13061 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2014 |
| End | 08/2015 |
| Description | Confidence in Concept 2014 |
| Amount | £700,000 (GBP) |
| Funding ID | MC_PC_14099 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2015 |
| End | 08/2016 |
| Description | Darwin Trust bequest |
| Amount | £100,000 (GBP) |
| Organisation | British Society for the History of Science (BSHS) |
| Department | Darwin Trust of Edinburgh |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2015 |
| End | 09/2016 |
| Description | Innovative therapeutics |
| Amount | £200,000 (GBP) |
| Organisation | Charles Wolfson Charitable Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2012 |
| End | 04/2014 |
| Description | Institutional Strategic Support Fund Y2 |
| Amount | £275,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2012 |
| End | 09/2013 |
| Description | Institutional Strategic Support Fund Y3 |
| Amount | £275,000 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2013 |
| End | 09/2014 |
| Description | Institutional Strategic Support Fund Y4-5 |
| Amount | £550,000 (GBP) |
| Organisation | Wellcome Trust |
| Department | Wellcome Trust Institutional Strategic Support Fund |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 09/2016 |
| Description | MRC Non-clinical Senior Fellowship |
| Amount | £2,500,000 (GBP) |
| Funding ID | MR/K024213/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2014 |
| End | 01/2020 |
| Description | Tres Cantos OpenLab |
| Amount | £108,470 (GBP) |
| Organisation | Tres Cantos Open Lab Foundation |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2015 |
| End | 07/2017 |
| Description | Wellcome Trust Senior Investigator Award |
| Amount | £2,360,250 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 09/2013 |
| End | 09/2020 |
| Description | project grant |
| Amount | £261,067 (GBP) |
| Organisation | Arch Therapeutics |
| Sector | Private |
| Country | United States |
| Start | 01/2017 |
| End | 12/2019 |
| Description | strategic award |
| Amount | £3,572,417 (GBP) |
| Organisation | Wellcome Trust |
| Department | Wellcome Trust Bloomsbury Centre |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 06/2013 |
| End | 07/2018 |
| Description | InhA fragment based lead generation - Tres Cantos Open Lab award |
| Organisation | GlaxoSmithKline (GSK) |
| Country | Global |
| Sector | Private |
| PI Contribution | Data from NMR fragment screen supported by Dundee CiC award. Project management, Drug Discovery leadership from DDU Tb group. UoD funding will also support Lead opinimsation efforts arrising from this work. |
| Collaborator Contribution | Chemistry supported by open lab award. Structural biology, biochemical screening for InhA, early efficacy and tox assays. |
| Impact | Access to GSK models and systems. Funding for Medicinal chemistry posts. |
| Start Year | 2015 |
| Description | Ubiquigent - DDU: DUB library |
| Organisation | Ubiquigent |
| Country | United Kingdom |
| Sector | Private |
| PI Contribution | The University of Dundee Drug Discovery Unit has developed a 500 member compound library of novle De-ubiquitinase targeted inhibitors. UoD has conducted pre-commercialisation basic research including developing in silico models of compound binding, virtual screening and library design and synthesis. The library that was generated was of sufficient interest to Ubiquigent that they wish to develop the asset as a new product line as part of a profit sharing agreement with UoD. |
| Collaborator Contribution | Using their DUB profiler platform, Ubiquigent are characterising the molecules developed by the University of Dundee Drug discovery group to determine whether novel DUB inhibitors have been identified. Ubiquigent are also developing a marketing and sales strategy around the DUB libray as a first of its kind product line. Ubiquigent will also conduct the sales and compound logistic elements of any commercialisaiton activities on the project. |
| Impact | Characterisation activities are ongoing but an agreement has been signed to cover commercialisaiton of the compound library |
| Start Year | 2015 |
| Description | Parkinsons Open doors day |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Participants in your research and patient groups |
| Results and Impact | around 30 patients and thier carrers attended the open days where they heard talks on the reserch we conduct and participated in tours. Oppertunity to pose questions to scientists and vice versa, as well as to state desired outcomes from our work. Patients and charities expressed excitment at work conducted in unit. Stimulated further fund raising. |
| Year(s) Of Engagement Activity | 2013,2014 |